Skip to main content
Figure 4 | Arthritis Research & Therapy

Figure 4

From: Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)

Figure 4

Distribution of global response rates (full, partial versus no response) in patients with various autoimmune diseases who received rituximab, as reported by the treating physician over a median (range) of 194 (180 to 1,407) days according to the underlying diagnosis. AIHA, autoimmune haemolytic anaemia; AITP, autoimmune thrombocytopenia; AS, ankylosing spondylitis; MP, microscopic polyangiitis; NMO, neuromyelitis optica; PA, psoriatic arthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; WG, ANCA-associated granulomatous vasculitis.

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us